International Clinical Trial: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459647) titled 'A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia' on March 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: MapLight Therapeutics

Condition: Schizophrenia

Intervention: Drug: ML-007C-MA

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 2026

Target Sample Size: 500

To know more, visit https://clinicaltrials.gov/study/NCT07459647

Published by HT Digital Content Services with permission from Health Daily Digest....